Viking Therapeutics Shares Fall Nearly 3% Overnight After Wider Q3 Loss
Viking Therapeutics shares fell nearly 3% overnight after the company posted a wider-than-expected quarterly loss. CEO Brian Lian said the obesity-drug launch timeline is more than two years away.
Shares of Viking Therapeutics (VKTX) fell nearly 3% overnight late Wednesday after posting a wider-than-expected quarterly loss, while CEO Brian Lian’s outlook for an obesity-drug launch more than two years away also sparked retail backlash.VKTX stock rose nearly 2% to $25.36 on Wednesday, bringing…